Georgia's Online Cancer Information Center

Find A Clinical Trial

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Status
Active
Cancer Type
Leukemia
Lymphoma
Non-Hodgkin Lymphoma
Trial Phase
Phase IV
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06876649
Protocol IDs
27202 (primary)
NCI-2025-03405
2024-517760-29-00
J2N-MC-JZNY
Study Sponsor
Eli Lilly and Company

Summary

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of
the long-term safety and efficacy of pirtobrutinib after completion of clinical studies
evaluating pirtobrutinib. The clinical studies that will feed into this master protocol
are referred to as originator studies. The master protocol will govern individual
study-specific appendices (ISAs) that will represent participants from the individual,
completed originator studies. These participants will have the opportunity to enter this
study and continue to receive treatment or continue follow-up visits. Overall, the master
protocol and the individual ISAs, when combined, define the investigations for this
study.

Eligibility

  1. Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.